These suggest that the non-pCR group in HER2-positive breast cancer is highly diverse in terms of drug sensitivity and recurrence risk and that the relationship between residual tumor volume and recurrence risk may not be as straightforward as it is in TNBC. This evidence concerns the gene ERBB2 and breast carcinoma.